Last reviewed · How we verify
NCT01670058
Pattern Of Use Of Belatacept In US Transplant Recipients
trial in Kidney Transplantation: Transplantation, Kidney in 5,000 participants. Completed in 12 June 2018.
12 June 2018
Quick facts
| Lead sponsor | Bristol-Myers Squibb |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 5,000 |
| Start date | 31 January 2012 |
| Primary completion | 12 June 2018 |
| Estimated completion | 12 June 2018 |
Conditions studied
- Kidney Transplantation: Transplantation, Kidney — all drugs for Kidney Transplantation: Transplantation, Kidney →
Sponsor
Bristol-Myers Squibb — full company profile →
Who can join
Eligibility, any sex, with Kidney Transplantation: Transplantation, Kidney. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
* The prevalence of Belatacept use * The characteristics of Belatacept users and the temporal trends in these characteristics * Characteristics of adult kidney-only transplant recipients who are treated with Belatacept vs. who are treated with Calcineurin inhibitors (CNI)-based regimens at the time of transplantation, and the temporal trends in these characteristics during 7 years post approval of Belatacept.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Patterns of belatacept use and risk of post-transplant lymphoproliferative disorder in US kidney transplant recipients: An analysis of the Organ Procurement and Transplantation Network database.
Cherikh WS, Kou TD, Foutz J, Baker TJ, et al · · 2025 · cited 3× · PMID 39792912 · DOI 10.1371/journal.pone.0311935
Verify or expand the search:
- PubMed search for NCT01670058
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Bristol-Myers Squibb trials
Trials by the same sponsor.
- NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
- NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
- NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
- NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
- NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01670058 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
- Last refreshed: 13 July 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01670058.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing